Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 18


One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel.

Simeone JC, Molife C, Marrett E, Frech-Tamas F, Effron MB, Nordstrom BL, Zhu YE, Keller S, Murphy BR, Nair KV, Vetrovec GW, Page RL 2nd, McCollam PL.

Am J Cardiovasc Drugs. 2015 Oct;15(5):337-50. doi: 10.1007/s40256-015-0147-y.


Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor.

Molife C, Frech-Tamas F, DeKoven M, Effron MB, Karkare S, Zhu Y, Larmore C, Lu J, McCollam P, Marrett E, Vetrovec GW.

J Med Econ. 2015;18(11):898-908. doi: 10.3111/13696998.2015.1060979. Epub 2015 Jul 10.


A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy.

Xie L, Frech-Tamas F, Marrett E, Baser O.

Curr Med Res Opin. 2014 Dec;30(12):2415-22. doi: 10.1185/03007995.2014.964853. Epub 2014 Sep 29.


Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.

Marrett E, Zhao C, Zhang NJ, Zhang Q, Ramey DR, Tomassini JE, Tershakovec AM, Neff DR.

Vasc Health Risk Manag. 2014 Apr 25;10:237-46. doi: 10.2147/VHRM.S54886. eCollection 2014.


LDL-C levels in US patients at high cardiovascular risk receiving rosuvastatin monotherapy.

Ashton V, Zhang Q, Zhang NJ, Zhao C, Ramey DR, Neff D, Tershakovec AM, Marrett E.

Clin Ther. 2014 May;36(5):792-9. doi: 10.1016/j.clinthera.2014.03.010. Epub 2014 Apr 24.


Total and low-density lipoprotein cholesterol in high-risk patients treated with atorvastatin monotherapy in the United Kingdom: analysis of a primary-care database.

Jameson K, Zhang Q, Zhao C, Ramey DR, Tershakovec AM, Gutkin SW, Marrett E.

Curr Med Res Opin. 2014 Apr;30(4):655-65. doi: 10.1185/03007995.2014.890926. Epub 2014 Feb 27.


Potential effects of reclassifying CKD as a coronary heart disease risk equivalent in the US population.

Foster MC, Rawlings AM, Marrett E, Neff D, Grams ME, Kasiske BL, Willis K, Inker LA, Coresh J, Selvin E.

Am J Kidney Dis. 2014 May;63(5):753-60. doi: 10.1053/j.ajkd.2013.11.014. Epub 2013 Dec 25.


Burden of peripheral arterial disease in Europe and the United States: a patient survey.

Marrett E, DiBonaventura Md, Zhang Q.

Health Qual Life Outcomes. 2013 Oct 22;11:175. doi: 10.1186/1477-7525-11-175.


Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting.

Simpson RJ Jr, Tunceli K, Ramey DR, Neff DR, Kern DM, Hsieh HM, Wertz DA, Stephenson JJ, Marrett E, Tomassini JE, Jacobson TA.

J Clin Lipidol. 2013 Sep-Oct;7(5):399-407. doi: 10.1016/j.jacl.2013.06.002. Epub 2013 Jun 18.


Cardiovascular risk factor burden, treatment, and control among adults with chronic kidney disease in the United States.

Foster MC, Rawlings AM, Marrett E, Neff D, Willis K, Inker LA, Coresh J, Selvin E.

Am Heart J. 2013 Jul;166(1):150-6. doi: 10.1016/j.ahj.2013.03.016. Epub 2013 May 1.


Primary nonadherence to statin therapy: patients' perceptions.

Harrison TN, Derose SF, Cheetham TC, Chiu V, Vansomphone SS, Green K, Tunceli K, Scott RD, Marrett E, Reynolds K.

Am J Manag Care. 2013 Apr 1;19(4):e133-9.


Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009-2010).

Wong ND, Chuang J, Wong K, Pham A, Neff D, Marrett E.

Am J Cardiol. 2013 Aug 1;112(3):373-9. doi: 10.1016/j.amjcard.2013.03.041. Epub 2013 Apr 30.


Automated outreach to increase primary adherence to cholesterol-lowering medications.

Derose SF, Green K, Marrett E, Tunceli K, Cheetham TC, Chiu VY, Harrison TN, Reynolds K, Vansomphone SS, Scott RD.

JAMA Intern Med. 2013 Jan 14;173(1):38-43. doi: 10.1001/2013.jamainternmed.717.


Physician reasons for nonpharmacologic treatment of hyperglycemia in older patients newly diagnosed with type 2 diabetes mellitus.

Marrett E, Zhang Q, Kanitscheider C, Davies MJ, Radican L, Feinglos MN.

Diabetes Ther. 2012 Nov;3(1):5. doi: 10.1007/s13300-012-0005-8. Epub 2012 Jun 15.


Reasons given by general practitioners for non-treatment decisions in younger and older patients with newly diagnosed type 2 diabetes mellitus in the United Kingdom: a survey study.

Zhang Q, Marrett E, Jameson K, Meiler S, Davies MJ, Radican L, Sinclair AJ.

BMC Endocr Disord. 2011 Oct 28;11:17. doi: 10.1186/1472-6823-11-17.


Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes.

Zhang Q, Rajagopalan S, Marrett E, Davies MJ, Radican L, Engel SS.

Diabetes Obes Metab. 2012 Feb;14(2):149-54. doi: 10.1111/j.1463-1326.2011.01498.x. Epub 2011 Oct 30.


Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain.

Marrett E, Stargardt T, Mavros P, Alexander CM.

Diabetes Obes Metab. 2009 Dec;11(12):1138-44. doi: 10.1111/j.1463-1326.2009.01123.x. Epub 2009 Sep 16.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk